symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
RPTX,5.14,-0.132483,141359,216365216,0,4.89-18.68,0.05,Repare Therapeutics Inc.,USD,0001808158,US7602731025,760273102,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.reparerx.com,"Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.",Mr. Lloyd Mitchell Segal,Healthcare,CA,180,857 412 7018,7210 Frederick-Banting,Montreal,QC,H4S 2A1,,0,https://financialmodelingprep.com/image-stock/RPTX.png,2020-06-19,False,False,True,False,False
